PT Merck Tbk (MERK.JK) Stock

MERK.JK logo

PT Merck Tbk

MERK.JKIndonesia
Healthcare

Company profile

PT Merck Tbk reported revenue of 1.20 trillion IDR for fiscal year 2025, up 15.8% from fiscal year 2024, and net income of 243.90 billion IDR. That is a net profit margin of 20.3% for fiscal year 2025. In Q2 2026 (the quarter ended June 30, 2026) revenue was 347.13 billion IDR, up 31.0% from a year before. In Q2 2026 it reported net income of 46.60 billion IDR, against net income of 9.32 billion IDR a year earlier. Our analysis of its filings shows revenue growing from 961.43 billion IDR in fiscal year 2023 to 1.20 trillion IDR in fiscal year 2025, 11.8% a year on average. PT Merck Tbk reports about 331 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About PT Merck Tbk

PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism. In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is based in Jakarta Timur, Indonesia. PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.

Leadership

  • Evie Yulin — President Director & Biopharma Director, 58
  • Bambang Nurcahyo — Finance Director & Director, 55
  • Eduan Tjong — Supply Chain & Operation Manager
  • Miranda Andamsari — Compliance Officer
  • Taufiq Wibowo — Head of Legal

How much revenue does PT Merck Tbk make?

PT Merck Tbk reported 1.20 trillion IDR in revenue for fiscal year 2025, up 15.8% from 1.04 trillion IDR in fiscal year 2024. In Q2 2026 revenue was 347.13 billion IDR.

What companies are similar to PT Merck Tbk?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), PT Tempo Scan Pacific Tbk (TSPC.JK), PT Darya-Varia Laboratoria Tbk (DVLA.JK), PT Pyridam Farma Tbk (PYFA.JK).

How has PT Merck Tbk's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.06 trillion IDR; FY2022, 1.12 trillion IDR; FY2023, 961.43 billion IDR; FY2024, 1.04 trillion IDR; FY2025, 1.20 trillion IDR.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees331
HeadquartersJakarta Timur, Indonesia
ExchangeJakarta
TimezoneAsia/Jakarta (WIB)

Contact & Links

Address
Jl. TB Simatupang No. 8, Jakarta Timur, 13760
Phone
62 21 2856 5600
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PT Merck Tbk (MERK.JK)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/MERK.JK

LinkedInLinkedInXXYouTubeYouTube